Investigating how certain immune signals affect lung inflammation from beryllium exposure
Role of Chemokines in Innate and Adaptive Immunity in the Lung
This study is looking at how certain immune signals in the body affect chronic beryllium disease, which can happen from working with beryllium, and it aims to find ways to better treat or prevent this condition for those who are affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10576294 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of specific immune signals, known as chemokines, in the development of chronic beryllium disease (CBD), which occurs due to workplace exposure to beryllium. The study examines how these signals lead to inflammation and the recruitment of immune cells in the lungs of affected individuals. By analyzing immune responses in both animal models and human patients, the research aims to identify key immune mechanisms that contribute to the disease. This could help in developing targeted therapies to manage or prevent CBD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been diagnosed with chronic beryllium disease or have a history of beryllium exposure.
Not a fit: Patients without a history of beryllium exposure or those not diagnosed with chronic beryllium disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage chronic beryllium disease and improve lung health for affected patients.
How similar studies have performed: Previous research has shown promising results in understanding immune responses related to other occupational lung diseases, suggesting potential for success in this area as well.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Atif, Shaikh M — University of Colorado Denver
- Study coordinator: Atif, Shaikh M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.